Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

Kurino, T; Matsuda, R; Terui, A; Suzuki, H; Kokubo, T; Uehara, T; Arano, Y; Hisaka, A; Hatakeyama, H

Hatakeyama, H (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Lab Clin Pharmacol & Pharmacometr, Chiba, Japan.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020; 8 (1):

Abstract

Background Recently, antiprogrammed cell death protein 1 (aPD-1) and antiprogrammed death-ligand 1 (aPD-L1) monoclonal antibodies (mAbs) have been app......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索